News & Updates

The addition of glofitamab – a CD20xCD3 T-cell engaging bispecific antibody (BsAb) – to gemcitabine and oxaliplatin (GemOx) chemotherapy improves survival in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) who have received at least one prior line of systemic therapy and are ineligible for autologous stem cell transplant, findings from the phase III STARGLO trial have shown.

Individuals with type 2 diabetes (T2D) treated in routine clinical care appear to fare better with glucagon-like peptide-1 receptor agonists (GLP-1RAs) than with dipeptidyl peptidase-4 inhibitors (DPP-4is), with GLP-1Ras being associated with lower rates of hyperkalemia and renin-angiotensin system inhibitor (RASi) medication discontinuation, as shown in an observational study.

Treatment with rucaparib in patients with newly diagnosed advanced ovarian cancer provides long-term improvements in progression-free survival (PFS) both in those with high and low risk of disease progression, as shown in the updated PFS analyses of the ATHENA-MONO study.

Adding anlotinib to gefitinib significantly improves progression-free survival (PFS) in treatment-naïve Chinese patients with EGFR-mutated (EGFRmut) advanced non-small-cell lung cancer (NSCLC), according to the results of the FL-ALTER phase III study.